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ABSTRACT
Background Squamous cell carcinoma of the lung is a
common cancer with 95% mortality at 5 years. These
cancers arise from preinvasive lesions, which have a
natural history of development progressing through
increasing severity of dysplasia to carcinoma in situ (CIS),
and in some cases, ending in transformation to invasive
carcinoma. Synchronous preinvasive lesions identiﬁed at
autopsy have been previously shown to be clonally
related.
Methods Using autoﬂuorescence bronchoscopy that
allows visual observation of preinvasive lesions within the
upper airways, together with molecular proﬁling of biopsies
using gene sequencing and loss-of-heterozygosity analysis
from both preinvasive lesions and from intervening normal
tissue, we have monitored individual lesions longitudinally
and documented their visual, histological and molecular
relationship.
Results We demonstrate that rather than forming a
contiguous ﬁeld of abnormal tissue, clonal CIS lesions can
develop at multiple anatomically discrete sites over time.
Further, we demonstrate that patients with CIS in the
trachea have invariably had previous lesions that have
migrated proximally, and in one case, into the other lung
over a period of 12 years.
Conclusions Molecular information from these unique
biopsies provides for the ﬁrst time evidence that ﬁeld
cancerisation of the upper airways can occur through cell
migration rather than via local contiguous cellular
expansion as previously thought. Our ﬁndings urge a
clinical strategy of ablating high-grade premalignant airway
lesions with subsequent attentive surveillance for
recurrence in the bronchial tree.
INTRODUCTION
The proposed progression model for squamous cell
carcinoma (SqCC) of the lung is a stepwise change
in morphology from the early, non-speciﬁc change
of squamous metaplasia to mild, moderate and
severe dysplasia (SD) to carcinoma in situ (CIS) and
ﬁnally invasive cancer.1 Although preinvasive
lesions such as SD and CIS are thought to be
precursors of invasive SqCC, not all progress to
malignant tumours.1 We have previously documen-
ted that a minority of high-grade lesions progress
to invasive carcinoma within 2 years of follow-up
with the majority remaining static or regressing.2
Importantly, the presence of these preinvasive
lesions predisposes to cancer development at
remote sites.2 3
An increasing body of evidence suggests that
genetic mutations accumulate at a preneoplastic
stage, long before clinical or histological detection.4
Clonal expansion of these mutants may not cause
morphological change but can predispose the epi-
thelium to subsequent tumour development,5 a
process known as ‘ﬁeld cancerisation’. Field cancer-
isation demonstrated in several organs6–12 was ﬁrst
proposed by Slaughter et al.13 They observed oral
cancers to grow multifocally at sites surrounded by
areas of abnormal, precancerous cells and proposed
the regional preconditioning of epithelium by an
unknown carcinogenic insult.13 Braakhuis et al14
subsequently suggested the precancerous ﬁeld was
monoclonal in origin, a deﬁnition that ﬁts well
with the observation of several preinvasive lesions
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Key messages
What is the key question?
▸ Are spatially distinct precancerous lesions of
the airways related?
What is the bottom line?
▸ We demonstrate that cells from carcinoma in
situ lesions are capable of migrating across
histologically normal epithelium and
establishing new clonal lesions and hence
propose a novel mechanism of ‘ﬁeld
cancerisation’ within human airways with
important implications for lung cancer
clinicians.
Why read on?
▸ Using longitudinal tracking of lesions, our study
provides a novel answer to arguments that
have run since the publication of the Franklin
paper (1997), which noted an identical
mutation in separate premalignant lesions
leading to speculation that either the mutation
occurred across the whole bronchial tree or that
identical mutations were occurring
independently generating new clones.
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carrying the same rare somatic TP53 mutation in the bronchial
tree of a patient at autopsy.15
Previous studies investigating the accumulation of somatic
changes in preinvasive and invasive lesions used specimens
taken at a single time point, often from surgical resection speci-
mens.16–18 The development of autoﬂuorescence bronchoscopy
(AFB) has improved detection of preinvasive lesions in the
lung,19 providing the means for the longitudinal tracing and
facilitating the anatomical and biological study of the natural
history of preinvasive lesions in situ. We developed our longitu-
dinal study of preinvasive lesions to help delineate both their
clonal and temporal relationship.
In our study, we wished to answer whether these lesions
occur in a ﬁeld of clonally related epithelium, whether lesions
with identical mutations occur independently or whether they
occur after migration through a genetically unrelated epithelium
and then expand in a new favourable environment or ‘niche’ at
a distant location. We combine temporal mapping of preinvasive
lung lesions using AFB with mutation analysis of biopsy samples
to measure the clonal expansion of these lesions within the tra-
cheobronchial tree and delineate the extent and mechanism of
‘ﬁeld cancerisation’. We focus on individuals with rare tracheal
CIS disease and examine their clonal and temporal relationship
with other preinvasive lesions. The ﬁrst patient described gives a
unique insight into the mechanism of preinvasive epithelial cell
migration and subsequent clonal expansion over a 12-year
period, the additional four patients further demonstrate that the
occurrence of tracheal CIS is usually preceded by clonally
related but spatially distinct lesions more distal in the airway.
METHODS
Patient recruitment
The University College London Hospitals (UCLH) Early Lung
Cancer Surveillance Program uses AFB to assess patients at high
risk for lung cancer. Eligibility criteria for inclusion into the
programme involve the detection of one or more preinvasive
lesions in the absence of clinically or radiologically detected
invasive carcinoma or development of preinvasive lesions at
remote sites from the site receiving curative treatment for car-
cinoma. All patients in the programme are investigated with
repeated AFB and CT or positron emission tomography/CT .
Full details of the surveillance protocol have been previously
described.2 20 Sequential AFB procedures allow the collection of
biopsies from both the same preinvasive lesion longitudinally
and the detection and biopsy of new lesions either de novo or
via spread from an initial lesion. Each lesion is biopsied by sep-
arate forceps to eliminate cross-contamination. Full informed
consent was obtained from all patients.
Tissue sectioning and laser capture microdissection
Approximately 10 serial sections of 8 μm thickness were cut
from each formalin-ﬁxed, parafﬁn embedded block. The ﬁrst
and last sections were stained with haematoxylin and eosin
using a standard protocol and reviewed by two independent his-
topathologists to identify areas of histologically abnormal epi-
thelium. Normal or preinvasive areas of the epithelium were
then microdissected separately from methyl green-stained sec-
tions (Vector Laboratories, USA) using the PALM Microbeam
system (Zeiss, Germany). Genomic DNA was extracted from the
captured cells by digestion in PicoPure proteinase-K buffer
(Arcturus, UK) according to the manufacturer’s instructions.
Tubes containing digestion buffer but no captured material were
included in each DNA extraction batch and served as negative
controls.
Mutational detection
DNA from the invasive cancer or most recent CIS lesion was
used to screen for somatic mutation(s) in TP53 (exons 5–8),
K-RAS (exon 1, codons 12–13) and CDKN2A (p16INK4a, exon
2) using nested-PCR. Preinvasive lesions collected longitudinally
from each patient were then examined at those genomic loci
mutated in the corresponding screening specimen.
Constitutional DNA from whole blood was also examined in
order to exclude the possibility of the detected genetic abnor-
mality being a germline mutation. The obtained sequence elec-
tropherograms were compared with the published reference
sequences using the basic local alignment search tool (BLAST).
To determine the assay sensitivity and the percentage of TP53
mutant cells that need to be present to allow detection of a
mutation, we serially diluted tumour DNA carrying the TP53
deletion with normal, wildtype control DNA. The sensitivity of
the PCR-based detection method was determined to be ≤5%.
PCR primer/product size details and ampliﬁcation reactions are
Table 1 Demographic and clinical characteristics of the patients with tracheal carcinoma in situ included in the study
Patient Sex
Smoking (pack
years)
Initial malignancy
(stage)* Site
Age
(surgery)
Site(s) of new tumour (histology/time to
diagnosis†)
Sites
tested
Specimens
analysed
1 M 60 SqCC (T1N0M0) LUL 58 Left completion pneumonectomy (SqCC) arising
from a region of LUL stump (M93)
19 46
2 M 30–40 SqCC (T1N0M0) LLL 72 LLL stump (SqCC/M48) 6 8
Right Lung (SqCC/M50)
LUL (CIS /M78)
Trachea (SD /M85)
3 M 47 SqCC (T1N0M0) LUL 66 Lower Trachea/LMB stump (both early invasive
SqCC/M42)
5 6
4 M 40 SqCC (T2N0M0) RUL 57 RUL stump (SqCC/M11)
Trachea posterior wall
(invasive SqCC/M11)
3 3
5 M 40 SqCC (T1N0) RML
RLL
70 RIB (CIS /M60) 6 7
*Refers to initial malignancy detected prior to patient’s referral to UCLH.
†Refers to the time interval between surgery and diagnosis of new SqCC/CIS.
CIS, carcinoma in situ; LLL, left lower lobe; LMB, left main bronchus; LUL, left upper lobe; RIB, right intermediate bronchus; RLL, right lower lobe; RML, right middle lobe;
RUL, right upper lobe; SqCC, squamous cell carcinoma; SD, severe dysplasia; UCLH, University College London Hospital.
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provided in the online data supplement (see online supplemen-
tary tables S1 and S2, respectively).
Mutation veriﬁcation
The Catalogue of Somatic Mutations in Cancer database
(http://www.sanger.ac.uk/genetics/CGP/cosmic; Cambridge, UK)
was used to verify all the somatic mutations identiﬁed.
Nucleotide changes in the electropherogram were considered as
true somatic mutations only when seen in the absence of any
background noise/artefact and were accepted only if conﬁrmed
by repeating the PCR from the original DNA lysate.
Loss of heterozygosity (LoH)
Constitutional blood DNA from patient 1 was ampliﬁed for
three microsatellite markers (D17S 1506, D17S 1678 and D17S
1881) using Qiagen’s Multiplex PCR kit (Crawley, UK) accord-
ing to manufacturer’s instructions and 50-tagged primers with
either HEX or FAM ﬂuorescent probes. Preinvasive and control
samples with sufﬁcient DNA were subsequently analysed for
LoH using only microsatellites found to be heterozygous in con-
stitutional DNA. Fragment analysis was carried out on an ABI
3100, and data were analysed using PeakScanner V.1.0 (Applied
Biosystems). LoH was calculated using the height ratio of the
Table 2 Tracing the spread of the TP53 p.E294fs*51 (c.880delG) mutant clone over time in patient 1
AFB
date Month Biopsy site Diagnosis AFB status TP53 status LoH/RoH (D17S 1881)
10/2000 M38 LUL stump CIS + Mutant LoH
LLL orifice (control) NAD − Wildtype RoH
LLL (control) NAD − Wildtype RoH
*MC (control) NAD − Wildtype RoH/RoH
RUL (control) NAD − Wildtype RoH
RLL (control) NAD − Wildtype RoH
03/2001 M43 LUL stump SD + Mutant LoH
07/2001 M47 LUL stump CIS + Mutant LoH
12/2001 M51 LLL (control) NAD − Wildtype RoH
01/2003 M64 Left main bronchus SD + Mutant N/A
07/2003 M70 LLL (control) NAD − Wildtype RoH
†LLL orifice SD + Mutant LoH /LoH
Proximal left main bronchus SD + Mutant LoH
Left main bronchus CIS + Mutant N/A
11/2003 M74 LLL (control) NAD − Wildtype N/A
Proximal left main bronchus CIS + Mutant N/A
05/2004 M80 LLL (control) NAD − Wildtype N/A
09/2004 M84 LLL (control) NAD − Wildtype N/A
04/2006 M104 MC CIS + Mutant N/A
MC (control) NAD − Wildtype N/A
08/2006 M108 Lower anterior trachea CIS + Mutant LoH
01/2007 M113 Lower lateral trachea CIS + Mutant LoH
04/2007 M116 Lower trachea CIS + Mutant N/A
03/2008 M127 RMB (control) NAD − Wildtype N/A
RMB MoD + Mutant N/A
Lower trachea (control) NAD − Wildtype RoH
08/2008 M132 MC/stump CIS + Mutant N/A
Proximal RMB medial wall CIS + Mutant LoH
Proximal RMB medial wall SD + Mutant N/A
01/2009 M137 RMB CIS + Mutant N/A
LMB stump CIS + Mutant LoH
07/2009 M143 Lateral wall of orifice to RMB CIS + Mutant LoH
Posterior wall proximal RMB CIS + Mutant LoH
Left pneumonectomy stump CIS + Mutant LoH
11/2010 M159 RMB MiD − Wildtype RoH
RMB Metaplasia − Wildtype RoH
MC CIS + Mutant LoH
MC MiD − Wildtype RoH
MC (control) NAD − Wildtype RoH
RML (control) NAD − Wildtype RoH
05/2011 M165 RML CIS + Mutant N/A
03/2012 M175 RML CIS + Mutant N/A
RLL CIS + Mutant N/A
08/2012 M180 Posterior wall of RMB SqCC + Mutant N/A
Month refers to post-lobectomy.
*At M38, two distinct areas of the MC were biopsied, providing two AFB and histology normal samples.
†At M70, two distinct AFB detected and histology-confirmed SD samples from the LLL orifice were analysed and found to carry the c.880delG. In total, 46 samples from 19 spatially
distinct areas were analysed over a period of 12 years (M38–M180).
AFB, auto-fluorescence bronchoscopy; CIS, carcinoma in situ; LLL, left lower lobe; LMB, left main bronchus; LoH, loss of heterozygosity; LUL, left upper lobe; MiD, mild dysplasia; MoD,
moderate dysplasia; N/A, not analysed due to insufficient DNA lysate; NAD, no abnormality detected; RLL, right lower lobe; RMB, right main bronchus; RML, right middle lobe; RoH,
retention of heterozygosity; RUL, right upper lobe; SD, severe dysplasia.
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two-allele peaks in tissue DNA after normalisation to the allele
peak heights from constitutional DNA. A change of at least
twofold in the allelic ratio was considered as LoH.
Microsatellite primer details for the LoH analysis are provided
in online supplementary table S3.
RESULTS
Patients were selected from the UCLH Early Lung Cancer
Detection Program. Of the 113 patients in this cohort with pre-
invasive lesions, 61 had follow-up data for more than
12 months, and 10 of these had an AFB detected and histologi-
cally conﬁrmed high-grade (SD or CIS) lesion in the trachea.
Eight of these had at least one visible high-grade lesion in the
distal bronchial tree with seven having documentation of distal
lesions prior to the tracheal CIS lesion. One of these patients
had no biopsies available for analysis, and two had no mutations
detected in the screened genes. The remaining ﬁve patients had
longitudinally collected specimens with a somatic TP53 muta-
tion. Patient demographics, clinical presentation and circum-
stances leading to the detection of preinvasive lesions are
summarised in table 1. All reported CIS lesions were detected
by abnormal autoﬂuorescence and histological conﬁrmation.
The number of months after initial presentation is documented
as Mx (eg, month 12—M12). Full details for each patient’s speci-
mens are summarised in tables 2 and 3. Samples ranged from
patient 1, who had 46 tissue samples analysed over a period of
12 years (2000–2012), to patient 4, who had three tissue
samples analysed over 2 months.
Clonally related preinvasive lesions appear over time and
are spatially distinct
Patient 1 underwent left upper lobectomy for SqCC (T1N0M0)
in 1997 (tumour 1, M0). He had occasional episodes of haem-
optysis but AFB was normal including the lobectomy stump
(M10). At M34 after further haemoptysis, CIS was detected near
the lobectomy stump and the patient entered the UCLH Early
Lung Cancer Detection Program. Sequencing of this CIS lesion
(M38) revealed the presence of a TP53 p.E294fs*51 deletion
(c.880delG, exon 8) (ﬁgure 1). At this time (M38), there were
no further AFB-detectable lesions and normal epithelium (to
AFB and histological analysis) biopsied as control tissue from six
separate areas (ﬁgure 1) was TP53 wildtype. The mutant clone
remained at the resection margins at M43 and M47. At M64, a
new AFB-detected spatially separate SD lesion in the left main
bronchus (LMB) was positive for the TP53 deletion. Three
further spatially distinct lesions in the left bronchial tree were
detected at M70 (both SD) and both harboured the identical
mutant clone. Normal epithelium lay between each lesion
(AFB-negative, histologically normal and TP53 wildtype) con-
ﬁrmed at M51, M70, M74, M80 and M84. The TP53 deletion
remained in a subsequent biopsy from a resampled CIS lesion
(M74). The patient underwent a completion left pneumonec-
tomy (M91) after developing a further SqCC within the left
lower lobe (LLL) (tumour 2), beyond the main airways detected
by CT scan.
A new CIS lesion at the MC (M104), detected a year later,
contained the same TP53 deletion (after previously being
normal and TP53 wildtype at M38). Adjacent, control
Table 3 Clonality assessment over time in patients 2, 3, 4 and 5
Patient Bronchoscopy date
Time
post-lobectomy (months) Biopsy site Diagnosis Mutated gene (exon) Mutation identified
2 07/2001 M30 MC (control) NAD – Wildtype
08/2002 M43 LUL SD TP53-7 p.C242F; c.725G>T
LLL stump SD TP53-7 p.C242F; c.725G>T
12/2002 M47 MC MoD TP53-7 p.C242F; c.725G>T
MC Metaplasia – Wildtype
LUL/lingula sub CIS TP53-7 p.C242F; c.725G>T
03/2003 M50 RLL segmentectomy CA KRAS p.E88*; c.262G>T
02/2006 M85 Trachea CA TP53-7 p.C242F; c.725G>T
3 05/2003 M3 MC (control) NAD – Wildtype
10/2003 M8 LUL stump SD TP53-5 p.V173L; c.517G>T
08/2005 M30 Left pneumonectomy stump SD/CIS p.V173L; c.517G>T
03/2006 M37 Trachea CIS p.V173L; c.517G>T
08/2006 M42 Left pneumonectomy stump SqCC p.V173L; c.517G>T
Lower trachea SqCC p.V173L; c.517G>T
4 07/2009 M9 Proximal RMB CIS TP53-5 p.V173L; c.517G>T
p.V157F; c.469G>T
09/2009 M11 RUL stump SqCC TP53-5 p.V173L; c.517G>T
p.V157F; c.469G>T
Posterior wall lower trachea SqCC TP53-5 p.V173L; c.517G>T
5 06/2004 M50 LLL (control) NAD – Wildtype
LUL (control) NAD – Wildtype
Right lobectomy stump MoD/SD TP53-7 p.C242R; c.724T>C
p.G244D; c.731G>A
11/2004 M55 Right lobectomy stump SD p.C242R; c.724T>C
p.G244D; c.731G>A
04/2005 M60 RIB CIS/Inv. p.C242R; c.724T>C
p.G244D; c.731G>A
Lower trachea CIS p.C242R; c.724T>C
p.G244D; c.731G>A
10/2005 M66 RMB polyp SD p.C242R; c.724T>C
p.G244D; c.731G>A
CIS, carcinoma in situ; LLL, left lower lobe; LUL, left upper lobe; RIB, right intermediate bronchus; RLL, right lower lobe; RMB, right main bronchus; RUL, right upper lobe; SD, severe
dysplasia.
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epithelium (AFB-negative, histologically normal) remained wild-
type. Three subsequent bronchoscopies at M108, M113 and
M116 detected new and spatially distinct CIS lesions in the
lower trachea. All sites tested positive for the deletion, conﬁrm-
ing a proximal spread of the mutant clone. At M127, the dele-
tion was detected for the ﬁrst time within the right main
Figure 1 Spread of the TP53 p.E294fs*51 mutant clone (exon 8) over time in patient 1. The mutant clone (red circle/ﬁlled red circle) was ﬁrst
detected at M38 in the left upper lobe (LUL) stump and spread over 142 months (M38–M180) in a distal-to-proximal direction towards the MC and
trachea and then over into the right lung. Control biopsies from autoﬂuorescence bronchoscopy-negative areas conﬁrmed histologically normal and
genetically wildtype intervening epithelium (shown as black star or ﬁlled black star). The part of the lung surgically removed by lobectomy (dashed
black line, LUL stump) is not shown. Completion pneumonectomy (M91) is depicted as a solid black line.
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bronchus (RMB). Surrounding normal biopsies obtained at the
same time were again wildtype. At M132, M137, M143, M165 and
M175, autoﬂuorescence demonstrated further spatially distinct
lesions of CIS and SD in the right lung and all contained the
identical TP53 deletion as detailed in table 2. Control biopsies
from AFB normal sites showing normal or metaplastic areas of
the right bronchial tree between AFB abnormal sites were TP53
wildtype.
Importantly, a CIS specimen obtained at M159 from a
resampled site in the MC was still found to carry the deletion,
but normal and mild dysplastic epithelium laser captured from
either side of the MC CIS lesion was again TP53 wildtype. The
TP53 mutation was ﬁnally traced in an invasive SqCC specimen
(tumour 3) from the posterior wall of the RMB at M180, almost
12 years after its ﬁrst detection in the left upper lobe (LUL)
stump (M38).
Based on these ﬁndings, we propose that the TP53 p.E294fs*51
clone originated at the LUL either prior to or within the
38 months of the lobectomy and subsequently skipped towards
the MC and trachea and then into the right lung, giving rise to
spatially distinct and clonally related lesions (table 2, ﬁgure 1).
DNA material from the original resected tumour (tumour 1, M0)
was not available. Further evidence of their clonal relationship is
provided by microsatellite–LoH analysis of a marker close to
TP53, which showed a consistent loss of the same allele in all CIS/
SD cases (table 2).
Of particular interest are the normal molecular ﬁndings of
control biopsies taken in between lesions and the normal epithe-
lium laser captured from the margins of lesions. Of the 46 biop-
sies analysed for TP53, 27 were CIS/SD (58.7%) and 19 were
normal (41.3%). All CIS lesions were AFB-detected and found
to harbour the TP53 deletion. In contrast, all AFB-negative
normal biopsies analysed were TP53 wildtype, indicating a
100% correlation between AFB and mutational status.
After noting the distal-to-proximal spread of these lesions
into the trachea, we went on to determine whether other
patients with tracheal CIS lesions had the same chronology and
clonal relationship.
Tracheal CIS occurs after secondary spread from a distal
clonally related preinvasive lesion
In early 1999 (M0), patient 2 underwent a left lower lobectomy
for SqCC (tumour 1, T1N0M0). CIS at the LLL stump resec-
tion margin was detected, and he entered into the surveillance
programme. Over the following 47 months, he developed three
new preinvasive lesions, each containing an identical TP53 p.
C242F, c.725G>T mutation (exon 7) (ﬁgure 2). The mutant
clone spread proximally from the LLL to LUL/lingula and
towards the MC. At M50, a CT scan and biopsy revealed a
T1N0M0 poorly differentiated SqCC beyond the bronchoscopi-
cally visible airway in the right lung. Molecular analysis of the
resected cancer revealed the presence of a K-RAS p.E88*,
c.262G>T mutation but no TP53 mutation, indicating that this
was an unrelated cancer (tumour 2). The CIS lesions within the
airway were static by AFB for three and a half years, but the
TP53 mutant clone was subsequently detected in a new lesion at
M85 in the trachea (ﬁgure 2). Histology showed an area of CIS
with local invasion (tumour 3; table 3).
Patient 3 had a left upper lobectomy for SqCC (T1N0M0) in
February 2003 (M0) and has since been under surveillance for
CIS at the resection margin. A TP53 p.V173L, c.517G>T muta-
tion was detected in a resection margin specimen at M8, while a
normal sample taken from the main carina at M3 was wildtype.
At M12, the patient underwent a left completion
Figure 2 Tracing of the common mutant clone over time in the tracheobronchial tree of patient 2. Tracing the TP53 c.725G>T clone (exon 7) over
42 months from the left lower lobe stump (M43) to the trachea (M85). A second, unrelated tumour (K-RAS c.262G>T) was detected in the right lower
lobe at M50.
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pneumonectomy for clinical suspicion of invasion due to nodu-
larity of the stump CIS lesion, but no evidence of microinvasive
disease was found at pathology. Continued AFB surveillance
later found the same mutation at the pneumonectomy stump
(M30), and at an AFB distinct lesion in the trachea (M37). The
patient eventually developed two microinvasive carcinomas at
the pneumonectomy stump and trachea (M42), both positive for
the c.517G>T mutation (ﬁgure 3; table 3), for which he
received photodynamic therapy at M44. We have shown previ-
ously the lesion at M8 and the pneumonectomy stump carcin-
oma at M42 to be monoclonal in origin based on a shared
common 3q telomeric amplicon.21
Patient 4 underwent a right upper lobectomy in October
2008 (M0) for poorly differentiated SqCC (T2N0). CIS at the
resection margin was histologically conﬁrmed, and the patient
was referred for surveillance. A sample of this lesion showed
two TP53 mutations: c.517G>T (p.V173L) and c.469G>T (p.
V157F) that matched a later developing CIS lesion obtained
from the proximal RMB. The resection margin lesion pro-
gressed to invasive cancer at M11. Interestingly a second SqCC,
detected at M11 within the posterior wall of the lower trachea,
was found to harbour the c.517G>T clone but not the
c.469G>T, indicating the c.517G>T was the earlier mutation
and cell migration from the original lesion occurred before the
second mutation (ﬁgure 4; table 3).
Patient 5 underwent a right lower and middle lobectomy for
SqCC (T1N0) in April 2000 (M0). Residual CIS was reported at
the resection margin. At referral to the centre (M50), AFB
Figure 3 Tracing of the common mutant clone over time in the tracheobronchial tree of patient 3. Distal-to-proximal spread of the c.517G>T clone
(TP53 exon 5) within 29 months from the left upper lobe stump (M8) to the trachea (M37). The clone must have arisen at the lower trachea earlier
than M37.
Figure 4 Tracing of the common
mutant clone over time in the
tracheobronchial tree of patient
4. Detection of the c.517G>T and
c.469G>T mutations (both TP53 exon 5)
at the right upper lobe stump (M11).
Only one mutation was detected at the
posterior wall of the trachea (M11),
suggesting this was the ﬁrst mutation
and these cells spread towards this site
before the second mutation occurred.
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detected MoD/SD at the lobectomy stump with genetic analysis
revealing two TP53 mutations: p.C242R, c.724T>C and p.
G244D; c.731G>A (both in exon 7), with neither of the two
mutant clones present in normal epithelium from the LUL and
LLL. At M60, the same mutations were detected in two new
lesions, one more proximally in the right intermediate bronchus
(RIB, CIS with microinvasion) and a second in the lower
trachea (CIS) (ﬁgure 5; table 3). At M66, a further lesion was
detected in the RMB (SD) again harbouring both mutations.
Hence, all ﬁve patients developed clonally related but spatially
distinct lesions over time spreading from distal-to-proximal
airways.
DISCUSSION
We have used genetic analysis to deﬁne the natural history and
clonal spread of preinvasive lesions identiﬁed by repeat AFB of
the tracheobronchial tree in patients over periods of up to
12 years. In doing so, we have been able to document in situ the
generation of multiple preinvasive lung cancer lesions giving
new insight into ﬁeld cancerisation of the lungs. Further, we
show in all ﬁve patients with tracheal CIS that disease starts in
the bronchial tree and moves proximally upwards into the
trachea forming spatially distinct lesions.
The data presented here conﬁrm that multifocal preinvasive
lesions most frequently derive from a common clonal ancestor
as suggested by the seminal paper by Franklin and colleagues15
rather than arising independently.14 Intriguingly, our AFB and
genetic data show these lesions, while clonal are not contiguous,
suggesting that cellular migration has occurred through the
bronchial tree, with subsequent clonal expansion in a new envir-
onment. One remarkable patient demonstrates clonally related
but physically distinct preinvasive lesions that moved in a
distal-to-proximal spread from the left bronchial tree, up into
the trachea, and down into the right bronchial tree over a
period of 12 years. This raises signiﬁcant biological questions
regarding the mobility of airway epithelium and the evolution-
ary dynamics of the mutant clones. The distance travelled by
spatially distinct clonal lesions over time gives us some idea of
the rate of mutant cell migration. If we examine patient 1, the
mutant clone moves from the LUL entrance to the right lower
lobe. This is 10.8 cm, indicating a migration rate of 0.075 cm/
month.
Our results support the concept of ‘ﬁeld cancerisation’ in the
lung but not by a mechanism previously postulated. Previous
hypotheses include the ‘ﬁeld of injury’ hypothesis (ﬁgure 6A),
where all cells in a deﬁned area are exposed to a damaging agent
delivering the same insult to every cell.22 Alternatively, an individ-
ual cell clone has been postulated to expand relentlessly, possibly
in response to injury, setting up a contiguous ﬁeld of a mutant
clone in which invasive disease can develop (ﬁgure 6B).23–25 Our
results clearly mitigate against the latter hypothesis by demonstrat-
ing neighbouring, intervening epithelium between clonally related
preinvasive lesions to be both normal in histology and wildtype
for the genetic loci tested.
It is possible that we have missed thin snakes of CIS, migrat-
ing through the normal epithelium joining the lesions; however,
we feel this is unlikely for a number of reasons. First, our
PCR-detection method detects mutant TP53 at levels below 5%
when mixed with wildtype DNA. Furthermore, the longitudinal
nature of our sampling would be expected to detect intervening
abnormal cells over time. The LLL of patient 1 was tested wild-
type at six different time points (M38–M84; table 2). Even if
very few mutant CIS cells were initially present at the LLL at
M38 that went undetected due to sensitivity issues, it might be
expected to be able to ﬁnd the mutation at a later time point
after cell expansion. There has also never been any autoﬂuores-
cent evidence of a snake of cells in any of the patients screened
within our surveillance study.
The hypothesis that these lesions occur independently would
mean that in our ﬁrst patient the identical TP53 deletion
occurred on at least 19 occasions, leading to pathologically
identical but clonally separate lesions. The detected TP53 dele-
tion does not lie within the mutational TP53 hotspot sites,26
and the statistical chances of the identical single deletion occur-
ring in each of the samples sequenced are inﬁnitesimally small.
Our patient 1 data clearly show clonal expansion. The
c.880delG mutation is reported just seven times in the total of
3128 simple TP53 sequence variants reported in the COSMIC
mutation database.27 Assuming the mutation frequency of
approximately 0.002 is representative of all neoplasia, the
chance of two TP53 mutant cells both having the same
c.880delG mutation is less than 5×10−6. This is further sup-
ported by the observation that all preinvasive lesions also had
the same pattern of allelic loss on 17p, implying that the
Figure 5 Tracing of the common mutant clone over time in the tracheobronchial tree of patient 5. Simultaneous detection of the c.724T>C and
c.731G>A clones (both TP53 exon 7) at the lobectomy stump 50 months postsurgery (M50) and distal-to-proximal spread towards the lower trachea.
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c.880delG mutation was always present on the retained allele.
Taken together, these ﬁndings suggest that it is highly unlikely
for two unrelated cells to independently develop the same
pattern of genetic defects, strongly indicating that these cells
share a recent common clonal ancestor.
Our data therefore indicate subsequent preinvasive lesions occur
as a result of individual cells or clusters of cells migrating and
becoming established in a new environment where they experience
a selective growth advantage (ﬁgure 6C). Interestingly, once on the
bronchoscopy surveillance programme, all ﬁve patients quit
smoking, indicating that the developments documented here are
not related to new smoking damage. A ﬁnal explanation for the
apparent discontinuity of mutant cells could be ‘healing’ of the
wildtype epithelium and concomitant fragmentation of the mutant
cells, but this does not ﬁt with the AFB ﬁndings.
These data are interesting when considering the details of
clonal evolution in the preneoplastic lung. The extensive clonal
expansion of TP53 mutant cells implies selection for these
mutants, perhaps a consequence of dysregulated apoptotic and
senescence machinery. However, the ‘patchiness’ of mutants sug-
gests that the ﬁtness may be slight, temporal or related to envir-
onmental factors, such that genetically wildtype cells are able to
intervene between, and so presumably outcompete, the mutant
cells. Our data suggest that the evolutionary dynamics constrain
the clonal expansion of TP53 mutants such that they are unable
to repopulate the entire epithelium in a contiguous sheet.
We cannot determine in our studies the cell of origin of these
lesions, although by their nature the lesions consist of keratin
14-expressing basal cells recently proposed to be progenitor
cells of the upper airway.28 29 Long lifespan, self-renewal and
the ability to replicate for extended periods of time support the
hypothesis of stem or progenitor cell-induced tumourigenesis.
Our study provides further evidence that longitudinally occurring
preinvasive lesions are clonally related and shows for the ﬁrst time
Figure 6 Proposed mechanisms of clonal spread of carcinoma in situ in the lung epithelium. (A) ‘Field of injury’. Growth of clonally unrelated,
multifocal lesions within a ﬁeld predisposed to the same change after exposure to a common damaging agent. (B) ‘Contiguous ﬁeld’. Continuous
expansion of a clone, giving rise to a patch of clonally related cells and formation of a progressively expanding contiguous ﬁeld. (C) ‘Cell breakaway
and migration’. Following formation of a ‘clonal unit’ from an initial cell that acquired a proliferative advantage through acquisition of a mutation, a
cell or group of cells breaks away from the unit and migrates via histologically normal and genetically wildtype epithelium in order to establish new
lesions within a suitable niche.
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that these lesions are actually spatially distinct. These data catalogue
ﬁeld cancerisation in the lung and suggest that the evolutionary
dynamics restrict mutant clones to grow in spatially distinct lesions
rather than repopulating the entire epithelium. In addition, we docu-
ment for the ﬁrst time that tracheal CIS frequently develops from a
distal CIS lesion in the bronchial tree. Our ﬁndings, therefore, dem-
onstrate that while individual premalignant lesions may appear stable,
they are capable of intra-airway migration. Currently it is not possible
to predict which lesions will spread or progress to invasive cancers.
Further study of the lesions that progress to cancer compared with
those that remain stable or regress may provide molecular targets for
the design of novel therapeutic approaches. Currently there are no
randomised studies describing the best approach of treating these
lesions. Treatments, however, should be tissue sparing because further
lesions are likely to occur. Importantly, post-treatment, surveillance
with detailed autoﬂuorescent examination over extended time
periods must also be offered to patients in order to detect subsequent
developing CIS lesions that had metastasised pretreatment.
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